ReviewHealthcare (Basel, Switzerland)2017
The Role of Lipid Biomarkers in Major Depression.
Review in Healthcare (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Exploring the bidirectional relationship between depressive disorder and dyslipidemia: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- BrainFrontiers in immunology · 2021Pooled it
- Article
- BrainEnrich: Revealing Biological Insights for Imaging-Derived Phenotypes Through Transcriptomic Enrichment.Human brain mapping · 2026Article
- The Association Between Serum Vitamin D and Lipid Levels in Patients With Depression: A Cross-Sectional Study.Alpha psychiatry · 2026Article
- Lipopolysaccharide induced mouse depression model can better simulate changes in peripheral blood FFAs in alMDD.PloS one · 2026Article
- Towards precision psychiatry: Metabolomics identifies three biological subtypes of depression.PLOS digital health · 2025Article
- Lipidomic analyses reveal the dysregulation of oxidized fatty acids (OxFAs) and acyl-carnitines (CARs) in major depressive disorder: a case-control study.BMC psychiatry · 2025Article
- Current Insight into Biological Markers of Depressive Disorder in Children and Adolescents: A Narrative Review.Antioxidants (Basel, Switzerland) · 2025Review
- Relationship Between Obesity and Depression Considering the Inflammatory Theory.International journal of molecular sciences · 2025Review
- Article
- Discriminating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and comorbid conditions using metabolomics in UK Biobank.Communications medicine · 2024Article
- Clinical Factors and Biomarkers Associated with Depressive Disorders in Older Patients Affected by Chronic Kidney Disease (CKD): Does the Advanced Glycation End Products (AGEs)/RAGE (Receptor for AGEs) System Play Any Role?Geriatrics (Basel, Switzerland) · 2024Article
- Examining the cross-sectional relationship of platelet/high-density lipoprotein cholesterol ratio with depressive symptoms in adults in the United States.BMC psychiatry · 2024Article
- Potential of niacin skin flush response in adolescent depression identification and severity assessment: a case-control study.BMC psychiatry · 2024Article
- High-density lipoprotein (HDL) as an indicator for alcohol use in a psychiatrically ill population.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Observational
- Depression and cognition are associated with lipid dysregulation in both a multigenerational study of depression and the National Health and Nutrition Examination Survey.Translational psychiatry · 2024Article
- Stress-induced stenotic vascular remodeling via reduction of plasma omega-3 fatty acid metabolite 4-oxoDHA by noradrenaline.Scientific reports · 2024Article
- The association between Metabolic Score for Visceral Fat and depression in overweight or obese individuals: evidence from NHANES.Frontiers in endocrinology · 2024Article
- Biomarker-Guided Tailored Therapy in Major Depression.Advances in experimental medicine and biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the UK, the lifetime-documented prevalence of major depressive disorder (MDD) is currently 10%. Despite its increasing prevalence and devastating impact on quality of life, the pathophysiological mechanisms underpinning MDD remain to be fully elucidated. Current theories of neurobiological components remain incomplete and protein-centric, rendering pharmacological treatment options suboptimal. In this review, we highlight the pivotal role of lipids in intra- and inter-neuronal functioning, emphasising the potential use of lipids as biomarkers for MDD. The latter has significant implications for improving our understanding of MDD at the cellular and circuit level. There is particular focus on cholesterol (high and low density lipoprotein), omega-3, and omega-6 polyunsaturated fatty acids due to established evidence in the literature of a link between atherosclerotic disease and major depression. We argue that there is significant potential scope for the use of such peripheral biomarkers in the diagnosis, stratification and treatment of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.